Working Media vs. Nonworking Costs in Pharma Programmatic
Classify pharma programmatic media, data, technology, measurement, creative, and agency costs without mistaking a higher working-media ratio for value.
The short answer
“Working media” usually means money that buys inventory, while “nonworking” covers services, data, technology, creative, and measurement. That split is useful for accounting, but it is not a measure of effectiveness. A higher working-media ratio can be worse if it removes the audience data, verification, or measurement needed to make the inventory valuable.
The leadership question is not “How do we maximize working media?” It is “Which costs create decision or outcome value, which are duplicated, and which scale with spend?”
Use a cost taxonomy that survives comparison
| Cost | Example | Ask |
|---|---|---|
| Inventory | Publisher or exchange clearing cost | What supply and audience did it buy? |
| Platform | DSP or serving fee | Is it percentage-based, fixed, or embedded? |
| Data | Audience, identity, contextual signals | What provenance, match, and exclusivity apply? |
| Quality | Fraud, viewability, suitability verification | Is the same control charged twice? |
| Measurement | Brand, HCP, patient, or Rx study | What decision changes because of it? |
| People | Strategy, activation, analytics, account service | Are scopes and seniority explicit? |
| Creative/approval | Production, adaptation, regulatory review | Is reuse realistic across formats? |
Report gross investment, net inventory cost, and each fee layer. Do not force every vendor into a universal label if contractual definitions differ; reconcile the labels instead.
Evaluate value, not just ratio
Run four tests:
- Necessity: Does the cost satisfy a regulatory, quality, audience, or learning requirement?
- Incrementality: Does it add capability, or duplicate something already included?
- Scalability: Does the charge rise with spend even when effort does not?
- Decision value: Could the output change allocation, creative, audience, or partner choice?
Measurement can look nonworking while preventing a much larger misallocation. Conversely, multiple dashboards that restate the same platform data may add little decision value.
Compare like with like
A managed-service quote may embed platform, data, and labor in one CPM. A self-service plan may show them separately. The cheaper visible platform fee is not necessarily the cheaper total route. Normalize both to a common basis and list excluded work.
Hypothetical comparison
Plan A reports 88% working media but excludes measurement and bills audience data separately. Plan B reports 76% and includes both. Once normalized, Plan A costs more and answers fewer business questions. These figures are illustrative, not market benchmarks.
Tradeoffs that deserve executive attention
Fixed measurement costs burden small pilots but may become efficient at portfolio scale. Percentage fees are simple but can reward more spend rather than more value. Premium supply may raise CPM while reducing waste. Cheap audience data may expand apparent scale while lowering eligible-person precision. None of these conclusions can be made from fee percentage alone.
Request contract clarity about rebates, credits, principal trading, data reuse, cancellation, and makegoods. These are commercial and legal topics; counsel and procurement should review actual terms.
Practical takeaway
Treat working/nonworking as a transparent ledger, not a quality score. The next step is to normalize every proposal into inventory, platform, data, quality, measurement, people, and creative costs, then attach an owner and business purpose to each line.
Sources
- Association of National Advertisers, Programmatic Media Supply Chain Transparency Study
- IAB Tech Lab, ads.txt
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.